Who Paid My Doc
Richard Ondrizek
Obstetrics & Gynecology Burleson, TX Medical Doctor
NPI 1902864853 CMS profile 313691
11797 South Freeway, Ste 242, Burleson, TX 76028
General payments
$4,646
Research payments
$0
Ownership & investment interest
$5
Research they led as principal investigator
$2,589,021
Through program year 2023, Richard Ondrizek of Burleson, TX is reported in the CMS Open Payments database as having received $4,646 across 19 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $2,589,021 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $5 across 5 holdings.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 89th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
9 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $13 | 1 | |
| 2021 | General | $194 | 10 | |
| 2020 | General | $4,384 | 5 | |
| 2019 | General | $55 | 3 | |
| 2024 | Ownership | $1 | 1 | |
| 2023 | Ownership | $1 | 1 | |
| 2022 | Ownership | $1 | 1 | |
| 2021 | Ownership | $1 | 1 | |
| 2020 | Ownership | $1 | 1 |
Beside peers
- Richard Ondrizek
- Obstetrics & Gynecology median
- Middle half of Obstetrics & Gynecology
- National median
In program year 2025, general payments to Richard Ondrizek were reported at $0. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.
Show as a table
| Year | Richard Ondrizek | Obstetrics & Gynecology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $55 | $172 | $62–$391 | $163 |
| 2020 | $4,384 | $94 | $36–$222 | $114 |
| 2021 | $194 | $136 | $42–$369 | $132 |
| 2022 | $0 | $160 | $50–$433 | $149 |
| 2023 | $13 | $169 | $56–$423 | $160 |
| 2024 | $0 | $152 | $50–$371 | $164 |
| 2025 | $0 | $158 | $51–$401 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
19 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Obstetrics & Gynecology in Texas
Devin Garza
Obstetrics & Gynecology · Austin, TX
Shawn Tassone
Obstetrics & Gynecology · Austin, TX
Dale Stovall
Obstetrics & Gynecology · Dallas, TX
Karyn-Anne Cumberbatch
Obstetrics & Gynecology · Missouri City, TX
Robert Asgharian
Obstetrics & Gynecology · El Paso, TX
Catherine Hansen
Obstetrics & Gynecology · Webster, TX
Related records
Obstetrics & Gynecology in Texas
Practitioners in the same specialty and state, ranked by reported value.
All Obstetrics & Gynecology
Everyone recorded under this specialty, nationwide.
Doctors in Texas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.